Publications

Publications

FILTER
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
Select product(s):
Select topic(s):
Phase:
pre clinical

RYSTIGGO® (rozanolixizumab-noli)

Generalized Myasthenia
 Gravis

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells <em>in vitro</em>

Qureshi S Omar, Sutton J Emma, Rosemary F Bithell et al. January 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis:  Two-year interim results form the open-label extension of the randomized BE RADIANT phase 3b trial.

Strober Bruce, Paul Carle, Blauvelt Andrew et al. May 2023
pre clinical

ZILBRYSQ® (zilucoplan)

Generalized Myasthenia
 Gravis

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Tang Guo-Qing, Tang Yalan, Dhamnaskar Ketki et al. August 2023
phase 2

RYSTIGGO® (rozanolixizumab-noli)

Generalized Myasthenia
 Gravis

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Bril Vera, Drużdż Artur, Grosskreutz Julian et al. May 2023
phase 3

ZILBRYSQ® (zilucoplan)

Generalized Myasthenia
 Gravis

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

James F Howard Jr, Bresch Saskia, Genge Angela et al. May 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab, or secukinumab: Results from phase III/IIIb trials.

Kokolakis Georgios, Warren B. Richard, Strober Bruce et al. February 2023
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: A systematic literature review and a network meta-analysis.

Armstrong April, K. Fahrbach, Leonardi Craig et al. July 2022
phase 4

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Bimekizumab self-injection devices: Two multicenter, randomized, open-label studies on self-administration by patients with psoriasis.

Bagel Jerry, Machala Magdalena, Hellot Scarlett et al. February 2022
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: A systematic literature review and a network meta-analysis.

Armstrong April, K. Fahrbach, Leonardi Craig et al. July 2022
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis

Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled results from phase 2 and phase 3 randomized clinical trials.

Gordon B. Kenneth, Langley G. Richard, Warren B. Richard et al. July 2022
phase 2

RYSTIGGO® (rozanolixizumab-noli)

Generalized Myasthenia
 Gravis

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

Bril Vera, Benatar Michael, Andersen Henning et al. February 2021